Backing New Index Fund, GSK, J&J Buy Into Asset-Centric Vision Of Biotech Future
Executive Summary
Index Life VI is the first life-sciences-only fund for Index; GSK’s Moncef Slaoui and J&J’s Paul Stoffels are on scientific advisory board.
You may also be interested in...
Six Questions For Janssen Pharma Chairman Paul Stoffels
Amid increasing competition, the need is to be the best in collaboration with academics, and not to rely on a single regulatory agency amid regulatory delays in China, stresses Johnson & Johnson senior executive Paul Stoffels in a wide-ranging exclusive interview with PharmAsia News.
Six Questions For Janssen Pharma Chairman Paul Stoffels
Amid increasing competition, the need is to be the best in collaboration with academics, and not to rely on a single regulatory agency amid regulatory delays in China, stresses Johnson & Johnson senior executive Paul Stoffels in a wide-ranging exclusive interview with PharmAsia News.
Medtech Strategic/Start-Up Partnerships: Structuring For Success
According to a panel of strategic investors speaking at a recent IN3 meeting, structured deals that can help manage risk for medtech start-ups seeking funding and strategics looking for growth opportunities are on the rise.